[Last updated on 09/16/2007 ]

RAM I. MAHATO, Ph.D.

Curriculum Vitae

PERSONAL INFORMATION

Work Address:        Ram I. Mahato, Ph.D.

                                  Associate Professor (Tenured)
                                  Department of Pharmaceutical Sciences
                                  University of Tennessee Health Science Center
                                  Cancer Research Building

                           19 South Manassas (Room 224)

                           Memphis, TN38103-3308

Tel: (901) 448-6929 (office), 448-6848 (Lab)
Fax: (901) 448-2099

                           E-mail: rmahato@utmem.edu
                           http://cop.utmem.edu/rmahato

 

Home Address:       8589 Bay Orchard Lane

                                 Cordova, TN 38018

 

Marital Status:      Married to Subhashini Mahato

Children:                Daughter: Kalika (DOB: August 15, 1997), Son: Vivek (DOB: April 27, 2004)

 

Date of Birth:      January 11, 1963

Place of Birth:     Janankpurdham, Nepal

Citizenship:         United States (naturalized, 2006)

 EDUCATION

 1992    Ph.D., Pharmaceutics and Drug Delivery, Department of Pharmaceutical Sciences, University of   Strathclyde, Glasgow, Britain

1989     B.S., Pharmaceutics, China Pharmaceutical University, Nanjing, China

1985     Diploma in Chinese, Beijing Language Institute, China

1983     ISc. (Grade 11-12), Physics and Biology, RRM Campus, Tribhuwan University, Nepal,

UNIVERSITY APPOINTMENTS

2005-Present   Associate Professor, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis

2001-2005       Assistant Professor, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis

2004-Present   Adjunct Associate Professor, Department of Biomedical Engineering, University of Tennessee Health Science Center, Memphis

1999-2001       Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah

1994-96           Research Scholar, Department of Drug Delivery Sciences, Faculty of Pharmaceutical Sciences, Kyoto University, Japan

1993-94           Postdoctoral Fellow, Departments of Chemical Engineering and Ophthalmology, Washington University, St. Louis

1992                Research Associate, Department of Pharmaceutical Sciences, University of Southern California, Los Angeles

 

OTHER WORK EXPERIENCE:

1999                Manager, Pharmaceutical Development, Copernicus Therapeutics, Inc.

1996-99           Senior Scientist, Gene Delivery Sciences, GeneMedicine, inc.

 

Teaching EXPERIENCE

·       PHSC114: Pharmaceutics 1: Dosage Forms to PharmD Students

Role: Instructor and Course Director

Direct Student Contact Hours: 16

Credit Hours: 5

Period: 2005-present

 

·       PHSC222: Pharmacogenomics (2-0)

Role: Instructor

Direct Student Contact Hours: 2

 

·       PHSC111: Intro to Pharmacy & Health Care Environment

Role: Instructor

Direct Student Contact Hours: 15

                                                                                                                                                                                                                                   

·       PHSC114.3: Pharmaceutics: Dosage Forms

Course Director: Ram I Mahato, Ph.D.

Role: Instructor

Direct Student Contact Hours: 30

Credit Hours: 3

Period: 2001-2004

 

·       PHSC911: Delivery and Biocompatibility of Protein and Nucleic Drugs to Graduate Students

Course Director: Ram I. Mahato, Ph.D.

Role:   Instructor

Direct Student Contact Hours: 45

Credit Hours: 4

Period: 2002-Present, offered annually

 

·       PHSC840: Special Topics on Site-specific Delivery of Proteins, Oligonucleotides and Genes

Course Director: Ram I. Mahato, Ph.D.

Role:   Instructor

Direct Student Contact Hours: 30

Credit Hours: 3~5, depending on students

 

·       PHCEU 7210: Biocompatibility  [University of Utah]

Course Director: Jindrich Kopecek, Ph.D.

Role:   Instructor

Direct Student Contact Hours: 9

Credit Hours: 2

Period: 2000-2001

 

·       PHCEU 7420: Delivery of Macromolecular Therapeutic Agents  [University of Utah]

Course Director: Sung Wan Kim, Ph.D.

Role:   Instructor

Direct Student Contact Hours: 4

Credit Hours: 2

Period: 1999-2001

 

PROFESSIONAL HIGHLIGHTS

·       Delivery and Targeting of Oligonucleotide and siRNA-based Therapies: Contributed extensively on the use of antisense and antigene oligonucleotides as well as siRNA for treating liver fibrosis, diabetes and cancer.

·       Cell-Based Therapeutics: Contributed extensively on genetic modification of human islets for improved islet transplantation.

·       Cytokine Gene Therapy: Contributed extensively on the use of interleukin-12 (IL-12), interferon-gamma (IFN-g), vascular endothelial growth factor (VEGF) and growth hormone gene delivery to tumor and diabetes animal models.

·       Design of Gene Delivery Systems: Developed polymer, lipid, lipopolymer and peptide-based systems to deliver and transfect oligonucleotides and genes to specific organs in vivo and different cell lines in vitro.  

·       Formulation Sciences: Formulated various small drugs, proteins, oligonucledotides and plasmids for in vitro and in vivo studies.

·       Drug Delivery and Pharmacokinetics: Determined the pharmacokinetic profiles of small molecules, proteins, oligonucleotides and genes using mice, rats and rabbits.

·     Nanoparticulate Carrier Systems: Developed various polymeric nanoparticulate carrier systems. 

·       Synthesis: Synthesized water soluble and insoluble lipopolymers, soluble steroidal peptides, cationic lipids, and conjugated galactose, mannose and FITC to polylysine for gene delivery.

·       Lyophilization: Lyophilized anticancer drugs and lipid/plasmid complexes.

·       Intracellular Trafficking: Investigated the mechanism of cellular uptake and intracellular trafficking of plasmids and oligonucleotides.

·       Adenoviral vectors: Compared both viral and nonviral vectors for gene delivery.

·    Biocompatibility and toxicology of polymeric and lipid carriers for drug targeting: Evaluated numerous lipid and polymer-based systems.

PROFESSIONAL SOCIETY MEMBERSHIPS:

American Association of Pharmaceutical Sciences

Controlled Release Society

American Society of Gene Therapy

American Chemical Society

American Diabetes Association

New York Academy of Science

American Association for the Advancement of Science

Pharmaceutical Society of Japan  

EDITORIAL ACTIVITIES

Editor:

Pharmaceutical Research

 

Editorial Board:

Journal of Drug Targeting

Expert Opinion on Drug Delivery

Ad hoc reviewer:

Advanced Drug Delivery Reviews, American Journal of Drug Delivery, Biochemistry, Biomacromolecules, Biophysical Journal, Chemistry and Physics of Lipids; Clinical Pharmacokinetics, Critical Reviews in Therapeutic Drug Carrier Systems, Diabetologica, Drug Development Industrial Pharmacy, Drug Discovery Today, European Journal of Pharmaceutical Sciences, Gene Therapy, Human Gene Therapy, International Journal of Pharmaceutics, ournal of Controlled Release, Journal of Gene Medicine, J. of Electrochemical Society, Journal of Pharmaceutical Sciences, Molecular Pharmaceutics, Molecular Therapy, Nucleic Acids Research, Pharmaceutical Research, and S.T.P. Pharma Sciences.

 

HONORS AND AWARDS

2006            Nonviral Gene Transfer Vectors Scientific Committee Member, American Society of Gene Therapy

2004            Workshop Chair, Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics,

                    31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004)

                    Invited Speaker, Modulation of Gene Expression by Antisense, Antigene and sRNAi,

                    31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004)

                   Invited Speaker, Viral Medicine? Never, Pearls of Wisdom, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004)

                    Editorial Boad: Expert Opinion on Drug Delivery (2004-present)

2003             Invited Speaker, Challenges of Antisense Oligonucleotide Delivery, 30th Controlled Release Society (CRS) Annual Meeting (Glasgow, UK)

                     Who’sWho in America (2003)

2002           Invited Speaker on Functional and Biospecific Polymers for Therapeutic Gene Delivery,

                     AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery (Arlington, VA)                   

2000              Invited Speaker on Introduction to Gene Therapy at Sunrise School of Pharmacy at the AAPS Annual Meeting (Indianapolis)

1999              Invited Speaker, Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT) (Jerusalem, Israel)

1995-96         Goho Foundation Fellowship (Japan) 

1994-95         Uehara Foundations Fellowship (Japan)

1989-92         Cancer Research Campaign PhD Studentship of the United Kingdom

1986               International Student Award by China Pharmaceutical University, China

1984-8           Undergraduate studies supported by the Ministry of Education, Nepal

NATIONAL AND INTERNATIONAL SCIENTIFIC REVIEW PANELS

  1. Grant Reviewer, Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense (August 15-17, 2007)

  2. Ad Hoc Grant Reviewer, Israel Science Foundation (March 2007)

  3. Ad Hoc Grant Reviewer, Wellcome Trust, Great Britain (January 2007)

  4.  Ad Hoc Grant Reviewer, Alberta Heritage Foundation for Medical Research, Canada (December 2006)

  5. Ad Hoc NIH Grant Reviewer, Nanoscience and Nanotechnology (Washington D.C., March and July 2004)

  6. Ad Hoc Grant Reviewer, James and Esther King Biomedical Research Program (2004-Present)

  7.  Ad Hoc Grant Reviewer, Engineering & Biological Systems (EBS) of Great Britain (April, 2004)

  8. Ad Hoc Grant Reviewer, American Institute of Biological Sciences (October-November, 2002)

  9. Ad Hoc Grant Reviewer, NIH Gene Therapy Panel (March, 2002)

SERVICE TO PROFESSIONAL ASSOCIATIONS

  1. Member, CRS 2008 Educational Workshop Review Committee, 35th Controlled Release Society Annual Meeting (New York, NY, 2008)

  2. Session Chair, Nanoencapsulation I, 34th Controlled Release Society Annual Meeting (Long Beach, California, 2007)

  3. Member, 2007 CRS/Jorge Heller Journal of Controlled Release Award Committee.

  4. Session Chair, "Biomaterials for Site-Specific Delivery and Targeting of Oligonucleotides and siRNA" and "Emerging Trends in Cell-based Therapeutics". National Biotechnology Conference (NBC), Boston, MA (June 18-22, 2006)

  5. Session Chair, "Delivery, Transport and Transcription, 9th Annual Meeting of the American Society of Gene Therapy (ASGT), Baltimore, MD (May 31-June 4, 2006)

  6. Short Course Chair, Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, 2005 AAPS Annual Meeting and Exposition (Nashville, 2005)

  7. Session Co-Chair, Delivery of Nucleotide-based Therapeutics, 32nd Controlled Release Society Annual Meeting (Miami, Florida, 2005)

  8. Short Course Chair, Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society Annual Meeting (Honolulu, Hawai, 2004)

  9. Session Co-Chair, Challenges for Oligonucleotide Delivery, 30th Controlled Release Society Annual Meeting (Glasgow, Scotland, 2003)

  10. Session Co-Chair, Therapeutic Gene/Oligonucleotide Delivery, 29th Controlled Release Society Annual Meeting (Seoul, Korea, 2002)

  11. Disposition of Nonviral Gene Delivery Systems and Oligonucleotides. Round-table. 1998 Annual AAPS meeting, San Francisco, CA. 11/18/98. (Role: Co-organizer along with Shankar Musunuri and Uday B. Kompella)


PATENTS & INVENTION DISCLOSURES

  1. Mahato RI, Narang AS , Cheng K, Fraga D and Gaber AO (2003) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation. Filed for patent by the University of Tennessee Health Science Center, Memphis

  2. Mahato RI, Maheshwari A and Kim SW (2005) Soluble steroidal peptides for nucleic acid delivery. US Patent# 6,875,611.

  3. Mahato RI, Han SO and Furgeson DY (2004) Cationic lipopolymer as biocompatible gene delivery agent. US Patent# 6,696,038.

BOOK EDITOR

1.  Mahato RI. Pharmaceutical Dosage Forms and Drug Delivery(2007), CRC Press, Inc., FL

2.  Mahato RI (Ed) Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press, Inc., FL

3.  Mahato RI and Kim SW (Eds) Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics (July 2002), Francis and Taylor, London.

 

 JOURNAL THEME ISSUE EDITOR

1.    Mahato RI (Ed) Special Issues on Gene Delivery and Targeting (1999 and 2000) Journal of Drug Targeting 7: 241-313; 7: 407-470; and 8: 1-66. 

2.   Mahato RI (Ed) Theme Issue on Challenges of Turning Nucleic Acids into Therapeutics (2000) Adv. Drug Del. Rev. 44 (2-3): 79-207. 

INVITED SPEAKER (National/International Meetings)

  1. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Fibrosis and Hepatitis, School of Pharmacy, University of Manchester, United Kingdom, October 18, 2007.

  2. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, Department of Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany, October 16, 2007.

  3. Delivery and Targeting of Oligonucleotides and siRNA, Pfizer Global Research & Development, St Louis, MO, September 27, 2007.

  4. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Fibrosis and Hepatitis, School of Pharmacy, University of Manchester, United Kingdom, October 18, 2007.

  5. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, Department of Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany, October 16, 2007.

  6. Delivery and Targeting of Oligonucleotides and siRNA, Pfizer Global Research & Development, St Louis, MO, September 27, 2007.

  7. Site-specific Delivery of Oligonucleotides and siRNA, Department of Macromolecular Science, Fudan University, Shanghai, China, May 31, 2007.

  8. Site-specific Delivery and Targeting of Nucleic Acid Drugs for Treating Liver Diseases, China Pharmaceutical University, Nanjing, China, May 30, 2007.

  9. Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.

  10. Site-specific Delivery of Nucleic Acids (ODNs and siRNA) for Treating Liver Fibrosis, University of London School of Pharmacy, April 26, 2007.

  11. ODN (antisense and antigene) and siRNA Delivery and Targeting, Industry and Health Authority Conference on: Oligonucleotide-based Therapeutics, Bethesda, MD, April 19-20, 2007.

  12. Site-specific Delivery of Oligonucleotides and siRNA for treating Liver Fibrosis, Endocrinology Grand Round, University of Tennessee Memphis, January 25, 2007.

  13. The Role of Scientific Journals on Our Travel to Gene and Nanoworld, Universidade de Sao Paulo, Brazil, August 29-31, 2006.

  14. Gene Therapy and Gene Silencing in Islet Transplant, Division of Endocrinology, University of Tennessee Memphis, August 22, 2006.

  15. Site-specific Delivery of Oligonucleotides and siRNA for Treatment of Liver Fibrosis, Faculty of Pharmaceutical Sciences, Utretch University, Netherlands, July 21, 2006

  16. Site-specific Delivery of TFO and siRNA for Treatment of Liver Fibrosis, School of Pharmacy, University of Southern California, Los Angeles, CA, March 31, 2006.

  17. Gene Expression and Silencing for Improved Islet Transplantation, School of Pharmacy, University of Wisconsin, WI, September 16, 2005.

  18. Targeted Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells for Treatment of Liver Fibrosis, School of Pharmacy, University of Toronto, Canada, June 2005.

  19. Site-specific Delivery of Triplex Forming Oligonucleotides for Treatment of Liver Fibrosis. School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.

  20. A Travel to Gene and Nanoworld: A seminar to PharmD students, School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.

  21. Modulation of Gene Expression by Antisense, Antigene and sRNAi’ 31th Annual Meeting of the Controlled Release Society, Hawai, July 2004.

  22. Viral Vector never!! Pearls of Wisdom,  31th Annual Meeting of the Controlled Release Society, Hawai, July 2004

  23. Viral and Non-viral Approaches to Human Islet Transplantation. Department of Allergy and Immunology, University of Tennessee, Memphis, December 8th, 2003

  24. Triplex forming Oligonucleotide Delivery, Enzon, Inc. in Piscataway, NJ. (October 2, 2003)

  25. Challenges for oligonucleotide delivery. 30th Annual Meeting of the Controlled Release Society, Glasgow, Great Britain, July 2003

  26. Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation, Department of Internal Medicinem Endocrinology and Diabetology, Universitat Sklinikum, Giessen, Germany, July 15, 2003

  27. Development of novel gene carriers and expression systems for the treatment of diabetes and cancer, Pharmaceutics and Biopharmacy at the Philipps-University, Marburg, Germany, July 16, 2003.

  28.  Development of novel gene delivery systems for the treatment of diabetes and cancer, Department of Biopharmaceutics and Pharmaceutical Technology, University of Saarland, Saarbrucken, Germany, July 18, 2003.

  29. From bench to business: Tips for academics considering industrial careers, UT Graduate Research Student Day, May 2, 2003

  30. Functional Polymer and Lipid-based gene delivery for treatment of cancer and diabetes, School of Biomedical Engineering, University of Tennessee Memphis, October 4, 2002.

  31. Development of gene delivery and expression systems for treatment of cancer and diabetes, Vascular Biology Center of Excellence, University of Tennessee Memphis, October, 2002.

  32. Gene delivery and expression systems for treatment of cancer and diabetes, Hepatitis C Group, University of Tennessee Memphis, September, 2002.

  33. Lipopolymeric Gene Delivery for the treatment of diabetes, Department of Materials Science, University of Tokyo, Japan, July 15, 2002.

  34. Nonviral Approaches for Gene Delivery to Human Islets, Division of Stem Cell Regulation Research, Osaka University, School of Medicine, Japan. July 17, 2002.

  35. Development of Synthetic Gene Carriers, Department of Chemistry, College of Natural Sciences, Seoul National University, South Korea. July 24, 2002.

  36. Polymeric Gene Delivery for the Treatment of Cancer and Diabeties, University of Nebraska at Omaha, March 11, 2002.

  37. Functional and Biospecific Polymers for Therapeutic Gene Delivery at AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery, Arlington , VA. (February 28 ~ March 1, 2002).

  38. Nonviral Gene Delivery, St. Jude’s Children’s Hospital, Memphis, November, 2001.

  39. Introduction to Gene Therapy at Sunrise School of Pharmacy Session at the AAPS Annual Meeting (Indianapolis), 2000.

  40. Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99).

RESEARCH ARTICLES 

  1. Chen Y and Mahato RI (2007) siRNA Pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. Antiviral Research (submitted)

  2. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific Triple Helix Formation with Genomic DNA. Biochemistry (in press)

  3. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2007) Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjugate Chem (in press)

  4. De Paula D, Bentley MV and Mahato RI (2007) Effect of iNOS and NF-kB gene silencing on β-cell survival and function. J Drug Target 15: 358-369.

  5. Jia X, Cheng K and Mahato RI (2006) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Molecular Pharmaceutics 4: 199-207.

  6. Narang AS, Sabek O,  Gaber AO, and Mahato RI (2006) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm Res 23: 1970-82. This paper appeared on the cover page of the journal.

  7. Ye Z, Cheng K, Guntaka RV and Mahato RI (2006) Receptor-mediated Hepatic Uptake of M6P-BSA-conjugated Triplex Forming Oligonucleotides in Rats. Bioconjugate Chem 17: 823-830.

  8. Cheng K, Ye Z, Guntaka RV and Mahato RI (2006) Enhanced hepatic uptake and bioactivity of type a1(I) collagen gene promoter specific triplex forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805.

  9. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution and Hepatic Uptake of Triplex Forming Oligonucleotides Against Type ?1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics 2: 206-217.

  10. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Targeted delivery of a triplex forming oligonucleotide to hepatic stellate cells. Biochemistry 44: 4466-4476.

  11. Narang AS, Thoma L, Miller DD and Mahato RI (2005) Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem 16: 156-168.

  12. Cheng K, Fraga D, Kotb M, Gaber AO, Guntaka RV and Mahato RI  (2004) Adenovirus-based vascular endothelial growth factor gene delivery to human islets. Gene Ther 11: 1105-1116.

  13. Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO and Mahato RI (2004) Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm Res. 21: 15-25.

  14. Mahato RI, Henry J, Narang AS, Sabek O, Fraga D, Kotb and Gaber AO (2003) Cationic lipid and polymer-based gene delivery to human pancreatic islets.  Mol. Ther. 7: 89-100.

  15. Wang D-A, Narang AS, Kotb M, Gaber OA, Miller DD, Kim SW and Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.

  16. Furgeson DY , Cohen RN, Mahato RI and Kim SW (2002) Design, Synthesis and Characterization of novel lipoparticulates for systemic gene delivery.  Pharm. Res. 19: 382-390.

  17. Maheshwari A, Mahato RI and Kim SW (2002) Biodegradable polymer-based interleukin-12 gene delivery: Role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.  Gene Ther. 9: 1075-1084.

  18. Benns M, Mahato RI and Kim SW (2002) Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine.  J. Contr. Rel. 79: 255-269.

  19. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW (2001) Folate-PEG-Folate-graft-polyethylenimine-based gene delivery.  J. Drug Target. 9: 123-139.

  20. Mahato RI, Lee M,  Han S-O, Maheshwari A and  Kim SW (2001) Intratumoral delivery of p2CMVmIL-12 using water soluble lipopolymers.  Mol. Ther. 4: 130-138.

  21. Han S-O, Mahato RI and  Kim SW (2001) Synthesis and characterization of water-soluble lipopolymer for gene delivery.  Bioconjugate Chem 12: 337-345.

  22. Maheshwari A, Mahato RI,  McGregor J,  Han S-O, Samlowski WE, Park J-S and  Kim SW(2000) Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment.  Mol Ther 2: 121-130.  This paper appeared on the cover page of the journal.

  23. Benns JM,  Choi J-S, Mahato RI, Park J-S and Kim SW (2000) pH sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer.  Bioconj Chem 11: 637-645.

  24. Nomura T, Yamada T, Mahato RI, Watanabe Y, Takakura Y and Hashida M (1998) Gene expression and antitumor effects following direct interferon-g gene transfer with naked plasmid DNA and DC-Chol liposome complexes in mice.  Gene Ther. 6: 121-129.

  25. Mahato RI, Anwer K, Tagliaferri F,  Meaney C, Leonard P, Chen W, French M, Wadhwa MS and Rolland A (1998) Biodistribution and gene expression of plasmid/lipid complexes after systemic administration in mice.  Hum Gene Ther 9: 2083-2099.

  26. Takagi T, Hashiguchi M, Mahato RI, Tokuda H, Takakura Y and Hashida M (1998) Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages.  Biochem Biophys Res Commun 245: 729-733.

  27. Mahato RI, Takemura S, Takakura Y and Hashida M (1997) Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol 53: 887-895.

  28. Takakura Y, Mahato RI, Yoshida M, Kanamaru T and Hashida M (1996) Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Res Develop 6: 177-183.

  29. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M (1996) Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 279: 284-290.

  30. Hashida M, Mahato RI, Kawabata K, Sawai K, Nishikawa M and Takakura Y (1996) Pharmacokinetics of proteins, oligonucleotides, and genes.  J Contr Rel 41: 91-97.

  31. Yoshida M, Mahato RI, Kawabata K, Takakura Y and Hashida M (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion systems. Pharm Res 13: 597-601.

  32. Mahato RI, Kawabata K, Nomura T, Takakura Y and Hashida M (1995) Physicochemical and pharmacokinetic characteristics of DNA/cationic liposomes complexes. J Pharm Sci 84: 1267-1271.

  33. Mahato RI, Kawabata K, Takakura Y and Hashida M (1995) In vivo disposition of plasmid DNA complexed with cationic liposomes. J Drug Target 3: 149-157.

  34. Mahato RI, Halbert GW, Willmott N and Vezin WR (1994) Micron-size biodegradable microspheres: Characterization and preparative techniques.  J. Nep. Pharm. Assoc. 18: 1-16. 

EDITORIALS OR COMMENTARIES

  1. Book Review: Mahato RI (2005) A. Rolland and S.M. Sulivan, Editors, Pharmaceutical gene delivery systems, Marcel Decker, New York (2004) (424 pp.), J Control Rel 104: 233-234.

  2. Mahato RI and Narang AS (2005) Need of closer alliances for turning nucleic acids into nanomedicines. CRS Newsletter 22(1): 22, 25, 31.

  3. Mahato RI (2000) Challenges of turning nucleic acids into therapeutics.  Adv Drug Deliv Rev 44: 79-80.

  4. Mahato RI (1999): Editorial: Plasmid-based gene therapy: Opportunities and challenges knock the millennium.  J Drug Target 7: 241-244.

  5. Mahato RI, Fons MP and A Rolland (1998) Nonviral gene therapy: From Bench to the Clinic.  CRS Newsletter 15: 9-11.

REVIEW ARTICLES

  1. Ye Z, Saleh H and Mahato RI (2007) Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (in press).

  2. Cheng K and Mahato RI (2007) Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst  (in press).

  3. De Paula D, Bentley MV and Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 131-456. 

  4. Narang AS and Mahato RI (2006) Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58: 194-243. This paper appeared on the cover page of the journal.

  5. Mahato RI (2005) Water insoluble and soluble lipids for gene delivery.  Adv Drug Del Rev 57: 699-712.

  6. Mahato RI, Cheng K and Guntaka RV (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery 2: 3-28.

  7. Mahato RI, Narang AS, Thoma L and Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-216.

  8. Han S-O, Mahato RI, Sung YK and Kim SW (2000) Development of Biomaterials for Gene Therapy.  Mol Ther 2: 302-317.

  9. Mahato RI (1999) Non-viral peptide-based approaches to gene delivery J. Drug Target. 7: 249-268.

  10. Mahato RI, Monera OD, Smith LC and Rolland A (1999) Peptide-based gene delivery.  Cur Opin Mol Ther 2: 226-243.

  11. Mahato RI, Smith LC and Rolland A (1999) Pharmaceutical perspectives of nonviral gene therapy.  Adv Genet 41: 95-156.

  12. Takakura Y, Mahato RI and Hashida M (1998) Extravasation of macromolecules.  Adv Drug Del Rev 34: 93-108.

  13. Mahato RI, Rolland A and Tomlinson E (1997) Cationic lipid-based gene delivery systems: Pharmaceutical perspectives.  Pharm Res 14: 853-859.

  14. Mahato RI, Takakura Y and Hashida M (1997) Nonviral vectors for in vivo gene delivery: Physiochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst 14: 133-172.

  15. Mahato RI, Takakura Y and Hashida M (1997) Development of targeted delivery systems for nucleic acid drugs. J Drug Target 4: 337-357.

  16. Takakura Y, Mahato RI, Nishikawa M and Hashida M (1996) Control of pharmacokinetics of drugs using macromolecular carriers. Adv Drug Del Rev 19: 377-399.

BOOK CHAPTERS

  1. Mahato RI, Ye Z and Kim WS (2006) Water soluble lipopolymers and lipopeptides for nucleic acid delivery. In: Friedmann T and Rossi J (eds) Gene Transfer: Delivery and expression of DNA and RNA, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, p. 501-506.

  2. Cheng K and Mahato RI (2006) Biopharmaceutical Challenges in Pulmonary Delivery of Proteins and Peptide.  in Meibohm B. (ed) Pharmacokinetics and Pharmacokinetics of Biotech Drugs, Wiley-VCH, p. 209-242.

  3. Mahato RI, Ye Z and Guntaka RV (2005) Antisense and Antigene Oligonucleotides: Structure, Stability and Delivery. In Mahato RI (ed) Biomaterials for Delivery and Targeting of Protein and Nucleic acid Drugs, CRC Press, Boca Raton, FL

  4. Mahato RI and Kim SW (2005) Water soluble lipopolymers for gene delivery. In Amiji MM (ed) Polymeric Drug Delivery:Principles and Applications, CRC Press, Boca Raton, FL, p 175-186.

  5. Mahato RI (2003) Pharmaceutical delivery systems and dosage forms. In Gourley D and Eoff J (eds) APhA’s Complete Review for Pharmacy, Castle Connolly Publishers, New York (2004)

  6. Mahato RI and Tomlison E (2001) Plasmid-based gene therapy.  In: AM Hillery, AW Lloyd and J Swarbrick (eds) Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists, Taylor & Francis, London, pp. 372-397.

  7. Mahato RI, Furgeson DY, Maheshwari A, Han SO and Kim SW (2000) Polymeric gene delivery for cancer treatment.  In: K.D. Park, I.C. Kwon, N. Yui, S.Y. Jeong and K. Park (eds) Biomaterials and Drug Deliver towards New Millennium, Han Rim Won Publishing Co., Seoul, Korea, pp. 249-280. 

  8. Takakura Y, Mahato RI, Nomura N, Sawai K, Yoshida M, Kanamuru T and Hashida M (1995) Development of delivery systems for antisense oligonucleotides. In: Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems (N Ogata, SW Kim, J Feijen and T Okano, eds), Springer, 357-358.

ABSTRACTS AND PRESENTATIONS (*speaker)

  1. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2007) Site-specific Delivery of Oligonucleotides to Hepatocytes. 34th Proc. Int. Symp. Control Rel. Bioact. Mater, Long Beach, CA (July 2007).

  2. Li F, Panakanti R and Mahato RI (2007) Gene Expression and Silencing for Successful Islet Transplantation. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  3. Chen Y , Ye Z and Mahato RI (2007)  siRNA Pool Targeting Different Sites of Human Hepatitis B Surface Antigen Efficiently Inhibits HBV Infection, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  4. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific Triple Helix Formation with Genomic DNA, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  5. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007)

  6. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007) 

  7. Cheng K and Mahato RI (2007) TGF-β1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007)

  8. *Cheng K and Mahato RI (2007) TGF-β1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007)

  9. *Mahato RI, Cheng K, Ye Z, Chen Yong and Zhu L (2007) Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (Shanghai, China, May , 2007).

  10. *Mahato RI, De Paula D, Jia X, Cheng K and Narang AS (2007) Gene expression and silencing for improved islet transplantation. Pharmaceutical Science World Congress (Amsterdam, The Netherlands, April 2007). 

  11. Jia X, Cheng K and Mahato RI (2006) Construction of Bicistronic Plasmid Encoding Human Vascular Endothelial Growth Factor (hVEGF) and Interleukin-1 Receptor Antagonist (hIL-1Ra) for Improving Human Islet Transplantation. AAPS Annual Meeting (San Antonio, TX, 2006)

  12. Cheng K, Miller DD and Mahato RI (2006) Application of TGF-β1 Specific siRNA for the Treatment of Liver Fibrosis. AAPS Annual Meeting (San Antonio, TX, 2006)

  13. Cheng K, Guntaka RV and *Mahato RI (2006) Conjugation with Cholesterol Enhances Hepatic Uptake and Bioactivity of Triplex Forming Oligonucleotides. 33rd Proc. Int. Symp. Control Rel. Bioact. Mater (Vienna, Austria).

  14. Ye Z, Guntaka RV and Mahato RI (2006) M6P-BSA-TFO for Treating Liver Fibrosis, National Biotechnology Conference (Boston, June 2006)

  15. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide-bovine serum albumin conjugate in rats. AAPS Annual Meeting (Nashville, TN, 2005).

  16. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide in rats. AAPS Annual Meeting (Nashville, TN, 2005).

  17. Narang A, Sabek O, Gaber A and Mahato RI (2005) Effect of interleukin-1 receptor antagonist and vascular endothelial growth factor gene expression on human islet graft survival and function. AAPS Annual Meeting (Nashville, TN, 2005).

  18. Narang A, Thoma L, Miller DD, Rao RK and Mahato RI (2005) Permeation of lipid-insulin conjugate across rat jejunum and Caco2 cell monolayer. AAPS Annual Meeting (Nashville, TN, 2005).

  19. Narang A and Mahato RI (2005) Comparative efficacy of interleukin-1 receptor antagonist and small interfering RNA mediated silencing of inducible nitric oxide synthase in rat pancreatic islets. AAPS Annual Meeting (Nashville, TN, 2005).

  20. *Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Site-Specific Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  21. *Narang AS, Fraga D, Gaber AO and Mahato RI (2005) Adenoviral Delivery of Interleukin-1 Receptor Antagonist Gene to Human Pancreatic Islets. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  22. Narang AS, Seth P, Rao RK, Miller DD and Mahato RI (2005) Transepithelial Permeation of Insulin and Insulin Derivatives. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  23. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution of Triplex Forming Oligonucleotides Against Typea1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  24. Ye Z, Guntaka RV and Mahato RI (2004) Targeting Triplex Forming Oligonucleotide to Hepatic Stellate Cells 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  25. Narang AS, Thoma L, Miller DD and Mahato RI (2004) Effect of Cationic Lipid Headgroups on Gene Transfer. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  26. *Mahato RI, Cheng K, Fraga D, Gaber AO and Guntaka RV (2004) Adenovirus-Based Vascular Endothelial Growth Factor Gene Delivery to Human Pancreatic Islets. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  27. *Mahato RI and Guntaka RV (2004) Modulation of Gene Expression by RNAi, Antisense and Antigene. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  28. Narang AS, Fraga D, Zhang C, Sabek O, Kotb M, A. Gaber AO and Mahato RI (2003) Ex vivo vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003)

  29. Cheng K, Fraga D, Guntaka RV, Kotb M, Gaber AO and Mahato RI (2003) Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003)

  30. *Mahato RI and Guntaka RV (2003) Challenges for Oligonucleotide Delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain).

  31. Narang AS , Cheng K, Henry J, Zhang C, Fraga D, Sabek O, Kotb M, Gaber AO and Mahato RI (2003) Lipid-based gene delivery to human pancreatic islets. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain)

  32. Kumar N, Z Ye, Thoma L, Miller DD and Mahato RI (2003) Design of PEI-based lipopolymeric carriers for gene delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain)

  33. Ye Z, Kumar N, Thoma L, Miller DD and Mahato RI (2003) Hydrophobization of cationic polymers for enhanced gene delivery. 6th Annual Meeting of the American Society of Gene Therapy (Washington, D.C.)

  34. Mahato RI , Wang DA, Narang AS,  Kotb M, Gaber AO, Miller DD and  Kim SW (2002) Synthesis of T-shaped water soluble lipopolymers for gene delivery. Proc. Int Symp. Control. Rel. Bioact. Mater. 29: (Seoul, Korea)

  35. Mahato RI, Henry J, Narang AS, Mitra S, Fraga D, Sabek O, Kotb M and Gaber AO (2002) Nonviral approaches for growth factor gene delivery to human pancreatic islet. Proc. Int. Symp. Controlled Rel. Bioact Mater. 29; (Seoul, Korea)

  36. Narang AS, J Henry, S Mitra, D Fraga, O Sabek, M Kotb, AO Gaber and RI Mahato (2002) Synthetic Vector for grouwth factor gene delivery to human islets. 5th ASGT Annual Meeting (Boston, MA)

  37. Wang DA, Narang AS, Kotb M, Gaber AO and Mahato RI (2002) T-Shaped water soluble lipopolymers for gene delivery. 5th ASGT Annual Meeting (Boston, MA)

  38. Fugeson DY, Yokman J, Mahato RI and Kim SW (2002) Biodistribution of insoluble lipatticulate-based system. Proc. Int. Symp. Control Rel. Bioact. Mater. 29: (Seoul, Korea)

  39.  Han S-O, Lee M, Mahato RI and  Kim SW(2001) Water-Soluble Lipopolymer/p2CMVmIL-12 Complex for Cancer Treatment. AAPS Annual Meeting, Denver (October, 2001).  

  40. Furgeson DY, Mahato RI and Kim SW (2001) Synthesis and characterization of insoluble lipopolymers for gene delivery.  AAPS Annual Meeting, Denver (October, 2001)

  41. Maheshwari A, Mahato RI and  Kim SW(2001) Design of novel steroidal peptides for gene delivery.  AAPS Annual Meeting, Denver (October, 2001)

  42. Mahato RI, Lee M, Han S-O, Maheshwari A, and Kim SW (2001) Water soluble lipopolymers for interleukin-12 delivery.  28th Int Symp on Control Rel Bioactive Materials, San Diego (June 2001)

  43. *Han S-O, Mahato RI and Kim SW (2001) Water soluble lipopolymer for gene delivery.  4th Annual Meeting of the American Society of Gene Therapy, Seattle (May 30-June 4, 2001) (This abstract was selected as one of the top 3 abstract by the American Society of Gene Therapy and S-O Han was awarded $1000 at the symposium on May 30-June 3, 2001).

  44. Mahato RI, Lee M, S-O Han, Maheshwari A and  Kim SW(2001) Water soluble lipopolymer-based interleukin-12 delivery.  10th Int Symp on Recent Advances in Drug Delivery Systems, Salt Lake City (February 2001)

  45. Mahato RI, Maheshwari A, Furgeson DY,  Han S-O and Kim SW(2000) Polymeric-gene carriers for cancer treatment.  Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00)

  46.  Benns JM,  Maheshwari A, Furgeson DY, Mahato RI and  Kim SW(2000) Folate-PEG-folate-graft-PEI as a gene carrier. Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00)

  47. Mahato RI, A Maheshwari A, McGregor J, Samlowski WE and Kim SW (2000) Polymeric carriers for intratumoral delivery of cytokine genes.  3rd Annual Meeting of American Society of Gene Therapy, Denver (31 May-4 June’00)

  48. *Mahato RI and Kim SW (1999) Tailor made polymeric gene carriers.  3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99)

  49. *Mahato RI, Anwer A, Meaney C, Tagliaferri F, Smith LC and Rolland A (1998) Factors influencing cationic lipid-based systemic gene delivery and expression.  Proc Int Symp Control Rel Bioact Mater 25: 176-177.

  50. Smith LC, Logan M, Tagliaferri F, Monera O, Mahato RI, Reimer D, Wilson E, Proctor B and Rolland A (1998) Size dependence for dispersion of DNA/cationic lipid complexes in solid tumors.  Fourth Cold Spring Harbor Gene Therapy Meeting, Sept'98.

  51. Freimark BD, Bishop JS, Blezinger HP, Deshpande DS, Mahato RI,  Florack VJ and Pericle F (1998) In vivo administration of plasmid/cationic lipid complexes induces a cytokine pattern distinct from cationic lipids and plasmids. Fourth Cold Spring Harbor Gene Therapy Meeting, Sept' 98.

  52.  *Mahato RI, T Kanamaru T, Takakura Y and Hashida M (1996) Stability and disposition of phosphorothioate oligonucleotides in mice.  116th Annual Meeting of Pharmaceutical Association of Japan, Kanazawa.

  53. *Mahato RI, Takakura Y and Hashida M (1996) Disposition and gene expression of plasmid DNA complexed with cationic carriers.  Proc Intl Symp Control Rel Bioact Mater 23: 265-266.

  54. *Mahato RI, Takakura Y and Hashida M (1996) Disposition of antisense oligonucleotides to the hepatocytes using macromolecular carrier systems.  Jpn Soc Drug Del Sys, July, Kyoto.

  55. Mahato RI, Yoshida M, Nomura T, Kawabata K, Takakura Y and Hashida M (1995) Physicochemical and disposition characteristics of plasmid DNA complexed with cationic liposomes.  Proc Intl Symp Control Rel Bioact Mater 22: 418-419.

  56. Takakura Y, Mahato RI,  Kawabata K, Sawai K, Yoshida M and Hashida M (1994) Pharmacokinetics of oligonucleotides disposition in the body.  1st Intl Antisense Conf Jpn, December, Kyoto.

  57. Mahato RI , C Thies C, Lubiniewski A and Ravi VN (1994) Polymer mixture nanoparticles for ocular drug delivery.  Invest Ophthalmol Vis Sci 35: 2218.

  58. Lee VHL, LeeYH, Ohdo S,  Zhu J and Mahato RI  (1994) Dosing time influence on the ocular and systemic absorption on topically applied b-adrenergic antagonists in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 35: 1387.

  59. Lee YH, Mahato RI, Chung RYB, and Lee VHL (1993) Corneal and noncorneal absorption of topically applied ?-adrenergic antagonists in the pigmented rabbit. Pharm. Res. 10: S359.

  60. Thies C, Mahato RI and Ravi VN (1993) Ocular drug delivery systems. Association of International Chemical Engineers Meeting.

  61. Mahato RI, Halbert GW, Willmott N and Whateley TL (1992) Preparation of microspheres for intra-articular administration.  Proc Int Symp Control Rel Bioact Mater 19: 341-342.

  62. Mahato RI, Halbert GW and Willmott N (1992) Preparation and characterization of microspherical delivery systems.  ICI Science Link Meeting, Mereside, England.

  63. Mahato RI, Willmott N and Vezin WR (1991) Preparative techniques for albumin microspheres.  Proc Int Symp Control Rel Bioact Mater 18: 375-376

  64. Mahato RI, Willmott N and  Vezin WR (1991) Preparation and characterization of albumin microspheres.  British Colloid Science Student Meeting, Nottingham.

ACADEMIC COMMITTEE ASSIGNMENTS

PhD Committees (Chair)

  1. Krishna Bhandari (2007-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of miRNA for treating Hepatocellular Carcinoma.

  2. Michael Kofi Danquah (2007-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Polymeric Micelles for Treating Prostate Cancer.

  3. Ningning Yang (2006-Presnet) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of siRNA for treating Hepatitis C.

  4. Feng Li (2006-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Growth Factor and Antiapoptotic Gene Delivery to Human Pancreatic Islets for treating Type I Diabetes.

  5. Lin Zhu (2005-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of siRNA for treatment of Hepatitis and Liver Fibrosis.

  6. Ravikiran Panakanti (2005-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Viral and Non-viral Gene Therapy and RNAi for Improving Islet Transplantation.

  7. Zhaoyang Ye (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Triplex Forming Oligonucleotide Delivery to Hepatic Stellate Cells. Currently working as a Postdoctoral Fellow, Department of Biomedical Engineering, John Hopkins University, Baltimore, MD.

  8. Kun Cheng (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Adenoviral Gene Delivery to Human Islets & Biodistribution and Delivery Systems of Triplex Forming Oligonucleotides for treatment of Liver Fibrosis. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Missouri Kansas City, MO.

  9. Ajit S. Narang (2001-2006). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Nonviral and Adenoviral Gene Delivery to Human and Rat Islets. Synthesis of Novel Cationic Lipids for Gene Delivery. Currently working at Bristol Myers Squibs, Inc.
     

PhD Committee Member:

  1. Hari Desu (2005-Presnt) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Drug Delivery and Lyophilization.

  2. Murali K. Divi (2004-2007) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Targeted Drug Delivery to Glioma Brain Tumors. Currently working at

  3. Chad Batson (2003-2005). Department of Molecular Sciences, University ot Tennessee Health Science Center.

  4. Darin Y. Furgeson (2000-2003). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Structural and Functional Effects of Polyethylenimine Gene Carriers. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Wisconsin, Madison, WI

  5. Jonathan M. Benns (1998 - 2001). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Polymeric Gene Carriers. Currently studying law at the University of Utah, Salt Lake City.

Advisor for Summer Students and Exchange Students

  1. Daniel de Paula (Feb-August 2006) Visiting graduate student from the Faculty of Pharmaceutical Sciences of Ribeiräo Preto at the Univerity of Säo Paulo in Brazil. Working in my laboratory as a Research Scholar to conduct research on Protein and siRNA Delivery.

  2. Houssam Hajj Houssein (June-July, 2006), B.S. student from Delta State University, Cleveland, Mississippi on a project entitled, "Site-specific Delivery of TFO for Treating Liver Fibrosis (100% responsibility)

  3. Br